Inflammatory Bowel Disease Treatment Market by Type (Crohn’s Disease, Ulcerative Colitis), Drug Class (TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-intergin, IL inhibitors, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by Route of Administration (Oral, Injectable) and Region – Global Forecast to 2027
The global inflammatory bowel disease market is projected to reach USD ~32 billion by 2027 from 24 billion in 2022, at a CAGR of 5% during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
Inflammatory bowel diseaseis defined as repetitive inflammation of gastrointestinal tract. Inflammatory bowel disease involves two conditions, Ulcerative colitis and Crohn’s disease. The prevalence of Inflammatory bowel disease is high in genetically susceptible individuals who have inappropriate immune response to intestinal flora.
The pharmaceutical industry is undertaking rapid and exceptional measures to bring more innovative drugs for inflammatory bowel disease patients. The inflammatory bowel disease drug market is witnessing growth due to an increase in development of personalized medicine and a robust pipeline of novel drugs.The global inflammatory bowel disease market is segmented based on type, drug class, distribution channel, route of administration and region. Based on type, the market is segmented into Crohn’s disease and Ulcerative colitis. Based on drug class, the market is divided into Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-Integrin, JAK inhibitors and others. Based on distribution channel, market is classified into hospital pharmacy, retail pharmacy and Online pharmacy. Based on route of administration, inflammatory bowel market is segmented into oral and injectable market. Based on region, the market is distributed into North America, Europe, Asia and the Rest of the World (RoW).
To know about the assumptions considered for the study, download the pdf brochure
The major players in the inflammatory bowel disease market are Elli Lilly (US), Biogen (US), Takeda Pharmaceutical company limited (Japan), Pfizer Inc.(US), UCB S.A.(Belgium), Abbvie Inc.(US) , Johnson & Johnson (US), Merck & Co.(US), Amgen Inc.(US), Novartis AG(Switzerland), Bristol Myers Squibb(US) and Celltrion(South Korea).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.11 KEY STAKEHOLDER AND BUYING CRITERIA
6 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
6.1 INTRODUCTION
6.2 CROHN’S DISEASE
6.3 ULCERATIVE COLITIS
7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
7.1 INTRODUCTION
7.2 AMINOSALICYLATES
7.3 CORTICOSTEROIDS
7.4 TNF INHIBITORS
7.5 IL INHIBITORS
7.6 ANTI-INTEGRIN
7.7 JAK INHIBITORS
7.8 OTHERS (IF ANY)
8 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)
8.1 INTRODUCTION
8.2 HOSPITAL PHARMACY
8.3 RETAIL PHARMACY
8.4 ONLINE PHARMACY
9 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
9.1 INTRODUCTION
9.2 ORAL MARKET
9.3 INJECTABLE MARKET
10 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
10.1 INTRODUCTIONS
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 ROE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 REST OF APAC
10.5 REST OF THE WORLD (ROW)
10.5.1 LATIN AMERICA
10.5.2 MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
11.4 MARKET SHARE ANALYSIS, 2021
11.5 COMPANY EVALUATION QUADRANT
11.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
11.7 COMPANY GEOGRAPHIC FOOTPRINT
11.8 COMPETITIVE SCENARIO
12 COMPANY PROFILES
(The details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view will be provided)*
12.1 ELI LILLY AND COMPANY
12.2 BIOGEN
12.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
12.4 PFIZER INC.
12.5 UCB S.A.
12.6 ABBVIE INC.
12.7 JOHNSON & JOHNSON.
12.8 MERCK & CO., INC.
12.9 AMGEN INC.
12.10 NOVARTIS AG
12.11 BRISTOL MYERS SQUIBB
12.12 CELLTRION
* Details on business overview, financial information, products/services portfolio, recent developments, MarketsandMarkets view might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS
13.7 AUTHOR DETAILS
Growth opportunities and latent adjacency in Inflammatory Bowel Disease Treatment Market